Key Figures
Staff | 150 |
Products in development | 16 |
Partnered products | 4 |
Cash for operations | CHF 104.8 million
(plus $ 100 million upfront from Takeda) |
Funding into | 2027
(assumes second ACI-35-related milestone payment of CHF25 million received in 2025 and no other milestones) |
Debt | None |
Shares outstanding | 99.4 million
(as of March 31, 2024; excluding treasury shares) |
Potential total milestones from partners | CHF 4.3 billion |